Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Short-term Investments (2020 - 2025)

Legend Biotech filings provide 6 years of Short-term Investments readings, the most recent being $70000.0 for Q2 2025.

  • On a quarterly basis, Short-term Investments fell 99.83% to $70000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $70000.0, a 99.83% decrease, with the full-year FY2024 number at $70000.0, down 89.44% from a year prior.
  • Short-term Investments hit $70000.0 in Q2 2025 for Legend Biotech, roughly flat from $70000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $185.8 million in Q3 2023 to a low of $70000.0 in Q4 2024.
  • Median Short-term Investments over the past 5 years was $50.0 million (2021), compared with a mean of $83.7 million.
  • Biggest five-year swings in Short-term Investments: skyrocketed 4258623.4% in 2021 and later crashed 99.95% in 2025.
  • Legend Biotech's Short-term Investments stood at $1.4 million in 2021, then soared by 12753.39% to $185.6 million in 2022, then crashed by 99.64% to $663000.0 in 2023, then plummeted by 89.44% to $70000.0 in 2024, then changed by 0.0% to $70000.0 in 2025.
  • The last three reported values for Short-term Investments were $70000.0 (Q2 2025), $70000.0 (Q1 2025), and $70000.0 (Q4 2024) per Business Quant data.